Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

595
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
595
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

806
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
806
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

367
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
367
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

526
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
526
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

1.1K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.1K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

768
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
768

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>LRP1</i> and <i>RAGE</i> Expression in the Frontal Cortex in the Alzheimer's Disease Ischemia Model During 2 Years of Follow-Up.

International journal of molecular sciences·2026
Same author

Markers of Antiseizure Treatment Efficacy in Children: A Review.

Journal of clinical medicine·2026
Same author

Aberrant Potassium Handling by Astrocytes and Epileptic Seizures: A Synthetic Update.

Acta physiologica (Oxford, England)·2026
Same author

The Relationship Between the Gross Motor Function Classification System, Functional Mobility Scale, Observational Gait Scale, and the Amsterdam Gait Classification in Children with Cerebral Palsy During Long-Term Treatment with Botulinum Toxin Injections and Combined Integrated, Intensive Rehabilitation.

Toxins·2026
Same author

Exploring molecular signatures in PURA syndrome using muscle proteomics and serum biomarkers.

Journal of neurology·2026
Same author

Alterations of Apolipoprotein A1, E, and J Genes in the Frontal Cortex in an Ischemic Model of Alzheimer's Disease with 2-Year Survival.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Oct 18, 2025

Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.2K

Selected Molecular Targets for Antiepileptogenesis.

Marek J Pawlik1, Barbara Miziak2, Aleksandra Walczak2

  • 1Department of Neurotoxicology, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland.

International Journal of Molecular Sciences
|September 28, 2021
PubMed
Summary

Developing new treatments for epilepsy is crucial as many patients resist current drugs. Research explores compounds like eslicarbazepine and biperiden for their potential to stop epileptogenesis, the process of developing epilepsy.

Keywords:
antagomirsantiepileptic drugsantioxidative drugsc-Fosepileptogenesisepileptogenesis markerslosartannonsteroidal anti-inflammatory drugs

More Related Videos

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

33.7K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.3K

Related Experiment Videos

Last Updated: Oct 18, 2025

Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.2K
Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

33.7K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epilepsy Research

Background:

  • Epileptogenesis is the process of normal brain developing into an epileptic one.
  • Drug resistance in epilepsy necessitates the development of causative treatments targeting epileptogenesis.
  • Current antiepileptic drugs often lack significant antiepileptogenic potential.

Purpose of the Study:

  • To review existing and potential antiepileptogenic therapies.
  • To identify compounds with the potential to halt or modify epileptogenesis.
  • To highlight the need for further research into early epileptogenesis markers and therapies.

Main Methods:

  • Review of existing literature on antiepileptogenic drugs and agents.
  • Evaluation of compounds including eslicarbazepine, lamotrigine, levetiracetam, losartan, and biperiden.
  • Analysis of preclinical models and limited clinical data for antiepileptogenic efficacy.
  • Investigation of c-Fos as a potential early marker of epileptogenesis.

Main Results:

  • Several drugs, including eslicarbazepine, lamotrigine, and levetiracetam, show promise as antiepileptogenic agents.
  • Non-antiepileptic drugs like losartan, biperiden, NSAIDs, and minocycline also exhibit antiepileptogenic potential.
  • Biperiden appears well-tolerated in patients with brain injuries and may reduce post-traumatic epilepsy incidence.
  • c-Fos is identified as an early marker related to seizure duration, not intensity, in epileptogenesis.

Conclusions:

  • A range of pharmacological agents, both antiepileptic and non-antiepileptic, are being investigated for their antiepileptogenic properties.
  • Preventive efficacy of these agents requires further verification in relevant models and clinical trials.
  • Identification of reliable early epileptogenesis markers, such as c-Fos, is essential for developing effective antiepileptogenic therapies.